Informative Presentation
15th Patient has been Dosed
Open Label Trial with Interim Results ( current results "Safety Profile is similar to the Phase I " no serious adverse effects to date).
1st week of December Presentation of Interim Data at the American Society of Hematology where 30,000 Specialists Attend.
1st Q 2025 Phase II data to be presented to the FDA ,, $$$$
Whats is important to note is that we now have a Biotech Fund Invested with us ,,, the amount of DD is significant when a fund applies $$$$$ as Funds need to make a return to their Investors so it signals to the market that SNT is highly likely to increase significantly in value,, also a Fund is as only good as its reputation and results ,,, these guys don't just throw money into companies ,,, TBH it was a confidence boost PLUS SNT are still going to pursue the funds owing to the Company the placement was swift and necessary.. and in todays economic climate demonstrates SNT is a significant Investment opportunity NZT
- Forums
- ASX - By Stock
- SNT
- Ann: Phase 2 blood cancer trial fully recruited
Ann: Phase 2 blood cancer trial fully recruited, page-12
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
|
|||||
Last
3.0¢ |
Change
-0.001(3.23%) |
Mkt cap ! $35.82M |
Open | High | Low | Value | Volume |
3.0¢ | 3.0¢ | 2.7¢ | $293.5K | 10.28M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 903730 | 2.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.1¢ | 361455 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 903730 | 0.029 |
4 | 1494345 | 0.028 |
6 | 1577070 | 0.027 |
3 | 1499999 | 0.026 |
3 | 524000 | 0.025 |
Price($) | Vol. | No. |
---|---|---|
0.031 | 361455 | 4 |
0.032 | 50000 | 2 |
0.033 | 300000 | 1 |
0.035 | 500000 | 2 |
0.036 | 243902 | 1 |
Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |